NIW Approved for Senior Scientist Developing Immunogenic Correlate-Guided Vaccines

Client’s Testimonial:

“I am incredibly grateful to the North America Immigration Law Group for their exceptional guidance and support throughout my EB-2 NIW petition process. As a Senior Scientist working in the field of infectious diseases and vaccine development, it was critical for me to partner with a legal team that truly understood the value and impact of my research. NAILG meticulously crafted a compelling petition that clearly articulated the national importance of my work on immunogenic correlate-guided vaccines. Their strategic approach, attention to detail, and deep expertise in handling scientific cases were instrumental in securing my approval, without even a Request for Evidence. I highly recommend NAILG to any researcher or scientist pursuing an NIW petition. Their professionalism and dedication are truly unmatched.”

On May 24^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Scientist in the Field of Infectious Diseases (Approval Notice).

General Field: Infectious Diseases

Position at the Time of Case Filing: Senior Scientist

Country of Origin: India

State of Residence at the Time of Filing: Massachusetts

Approval Notice Date: May 24^th, 2025

Processing Time: 11 months, 7 days

Case Summary:

A client entrusted the North America Immigration Law Group (NAILG) with the preparation and filing of her EB-2 NIW petition. Her field of research—infectious disease therapeutics and vaccine development—places her at the forefront of public health innovation. By showcasing her pioneering work on immunogenic correlate-guided vaccines and her proven record of impactful scientific contributions, we successfully secured her petition’s approval without a Request for Evidence (RFE).

Developing Next-Generation Vaccines for Infectious Disease Mitigation

Our client’s research focuses on designing immunogenic correlate-guided vaccines to mitigate the global and national burden of diseases such as tuberculosis, malaria, measles, and Hepatitis B. Her work supports the development of therapeutic and prophylactic solutions using advanced molecular tools and high-throughput technologies.

Her studies have significantly advanced the understanding of how host-pathogen interactions can be modulated to improve immunity. Through her position at a leading U.S. biotechnology company, she continues to direct discovery-stage vaccine development programs that improve public health preparedness and combat pandemic-level threats.

Her Scientific Work Has Earned Broad Recognition

- 13 peer-reviewed journal publications, including 4 first-authored articles
- 353 citations across microbiology and immunology literature
- 4 publications ranked in the top 10–20% most cited in the field of immunology for their publication years
- 33 completed peer reviews for top-tier scientific journals

These metrics demonstrate the scholarly impact and authoritative voice she holds within her domain.

Notable Scientific Contributions Include:

● Targeting Protein Kinase G (PknG) for Tuberculosis Treatment: She demonstrated the viability of PknG deletion and inhibition as a therapeutic strategy, reducing Mtb survival and relapse potential in mouse models.
● Host-Directed Therapy Using SIRT2 Inhibitors: Her research revealed how modulating host epigenetic responses through SIRT2 inhibition enhances immune activation and TB treatment efficacy.
● Characterization of Mtb Survival Proteins (FtsQ, AosR, PPE2): Her discoveries advanced our understanding of pathogen resistance mechanisms and led to the identification of novel vaccine targets.

Her work has not only been cited extensively by global researchers but has also influenced ongoing projects in host-pathogen biology, vaccine design, and epigenetic immunotherapy.

NAILG’s Strategic Approach: Establishing National Interest

Our legal strategy emphasized how her proposed endeavor aligns with areas designated as “critical and emerging technologies” by the U.S. government, such as genome engineering and viral delivery systems. We also highlighted how her published work not only contributes to scientific knowledge but also informs practical vaccine development efforts that support American health and biosafety goals.

Through expert references, robust evidence of her citation metrics, and detailed documentation of her past and ongoing success, we established that:

● Her work has substantial merit and national importance.
● She is well-positioned to continue advancing her research.
● Waiving the job offer requirement would benefit the United States.

The final approval, issued without an RFE, underscores the strength of both the client’s qualifications and the legal arguments advanced by NAILG.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.